Dermatology · Williamsport, PA
NPI
1447227707
Since 2006
Specialty
Dermatology
Code 207N00000X
Group practices
1
Medicare group memberships
Hospitals
4
Hospital affiliations
1205 Grampian Blvd Ste 1a
Williamsport, PA, 17701
Phone (570) 326-8060
Groups this clinician bills Medicare through
Medicare paid, 2024
$271K
5,934 services
Medicare patients, 2024
1,411
Average age 75
Drug cost, 2024
$2.7M
2,194 prescriptions
Company payments, 2025
$17.02
From 1 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Sabrina K Mikita was code 17003 (destruction skin lesion), 1,333 times for 363 patients. In total Sabrina K Mikita billed 5,934 services in 55 codes, and Medicare paid $271K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-01-27.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 17003 Destruction Skin Lesion | Office | 1,333 | 363 | $4.65 | $6,198 |
| 99214 Office E&M - Established | Office | 1,088 | 899 | $83.60 | $91K |
| J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 877 | 89 | $0.65 | $574 |
| 17000 Destruction Skin Lesion | Office | 601 | 565 | $34.04 | $20K |
| 17110 Destruction Skin Lesion | Office | 527 | 490 | $71.63 | $38K |
| 99204 Office E&M - New | Office | 289 | 289 | $100.86 | $29K |
| 17004 Destruction Skin Lesion | Office | 251 | 197 | $105.73 | $27K |
| 99213 Office E&M - Established | Office | 251 | 243 | $49.83 | $13K |
| 11102 Skin Biopsy | Office | 159 | 154 | $57.60 | $9,159 |
| 96372 Injection Administration | Office | 103 | 82 | $8.80 | $906 |
| 17262 Destruction Skin Lesion | Office | 60 | 53 | $105.11 | $6,307 |
| 17111 Destruction Skin Lesion | Office | 57 | 51 | $83.23 | $4,744 |
| 11301 Removal or Shaving of Skin Growth | Office | 54 | 49 | $66.96 | $3,616 |
| 99203 Office E&M - New | Office | 29 | 29 | $66.75 | $1,936 |
| 11302 Removal or Shaving of Skin Growth | Office | 27 | 23 | $75.59 | $2,041 |
By year: 2022 $292K for 7,091 services; 2023 $253K for 6,134 services; 2024 $271K for 5,934 services.
Medicare prescription drug claims, 2024
In 2024, the drug Sabrina K Mikita prescribed most often to Medicare patients was Triamcinolone Acetonide, with 436 prescriptions and refills. In total Sabrina K Mikita wrote 2,194 Medicare prescriptions that cost $2.7M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Triamcinolone Acetonide Generic | 436 | 571 | 259 | $4,629 |
| Betamethasone Dipropionate Generic | 200 | 232 | 113 | $7,347 |
| Minocycline Hcl Generic | 117 | 141 | 50 | $3,855 |
| Clobetasol Propionate Generic | 100 | 118 | 45 | $6,245 |
| Humira(Cf) Pen Adalimumab | 73 | 73 | Under 11 | $699K |
| Terbinafine Hcl Generic | 71 | 112 | 42 | $758 |
| Metronidazole Generic | 61 | 66 | 33 | $4,847 |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 54 | 54 | 21 | $652 |
| Dupixent Pen Dupilumab | 53 | 53 | Under 11 | $200K |
| Cephalexin Generic | 51 | 51 | 34 | $258 |
| Prednisone Generic | 48 | 48 | 42 | $238 |
| Cosentyx Sensoready (2 Pens) Secukinumab | 47 | 47 | Under 11 | $371K |
| Spironolactone Generic | 47 | 49 | Under 11 | $551 |
| Hydroxyzine Hcl Generic | 45 | 50 | 19 | $422 |
| Hydrocortisone Generic | 39 | 39 | 24 | $329 |
Brand drugs: 353 claims; generic drugs: 1,841 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Sabrina K Mikita $17.02 ($17.02 in general payments such as food, travel and fees) from 1 company. The largest payer was Abbvie Inc. with $17.02.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 1 | $17.02 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.